KNOWING more could be a turning point for your patients

As obesity rates continue to climb, so does the population-wide risk for metabolic and cardiovascular diseases.1 However, many patients are unaware of their own risk, and as a result, may not take action to prevent disease progression. The new Metabolic Risk Panel from Quest Diagnostics-Cleveland HeartLab Cardiometabolic Center of Excellence can provide you with deeper insight into the cardiometabolic status of your patients.

Many of your patients are at a crossroads

The US is grappling with a metabolic disease epidemic. More than 1 in 3 adults struggle with obesity,2 which can lead to type 2 diabetes and cardiovascular disease.

  • 1 in 3 US adults has metabolic syndrome3
  • 84 million adults have prediabetes, but 90% don’t know it4
  • 30 million adults have progressed to type 2 diabetes5
  • In 2017, the total estimated cost of diagnosed diabetes was $327 billion4
 
Read more
Read less

A powerful new way to point your patients in the right direction

The new Metabolic Risk Panel from Quest Diagnostics-Cleveland HeartLab Cardiometabolic Center of Excellence includes the following components.

  • Apolipoprotein B (ApoB)
  • Insulin Resistance Panel with Score
  • HbA1c
  • Lipid panel
 
Read more
Read less

Bring risk to light earlier, for a clearer path ahead

The Metabolic Risk Panel allows for even earlier risk identification, offering deeper insight into the cardiometabolic status of your patients than any one test alone.

  • Measuring ApoB with triglycerides can help you assess cardiovascular risk as well as changes in lipid metabolism that are associated with early stages of metabolic dysfunction
  • LDL-C and non-HDL-C measurements can be used with ApoB to identify lipid discordance, uncovering risk that might otherwise be overlooked when LDL-C levels appear optimal
  • Coupling HbA1c with the Insulin Resistance Panel with Score can provide insight as to where a patient may be on the metabolic risk continuum
 
Read more
Read less

Changing the course of disease progression

The Metabolic Risk Panel supports your conversations with patients, providing you with more information to encourage them to make some of the following lifestyle modifications.

  • Eating a healthier diet lower in carbohydrates and higher in protein, monounsaturated fat, and soluble fiber
  • Losing weight to bring BMI into the lower end of the overweight range
  • Exercising for a minimum of 3 days per week
  • Enrolling in a diabetes prevention program, such as the 4myheart® personalized care program
 
Read more
Read less

Course-correct for better outcomes

The Metabolic Risk Panel can provide the information you need to help your patients course-correct earlier with lifestyle modifications, for better health outcomes.

Test Name

Patient Preparation

Test Code

CPT Codesa

Metabolic Risk Panelb

Overnight fasting required

39447

80061, 83036, 82172, 83525, 84681

aThe CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

bIf ordering through Cleveland HeartLab, panel components are: Cholesterol, Total (C117), HDL Cholesterol (C118), Triglycerides (C119), Lipid Panel (C906), Hemoglobin A1c (C145), Apolipoprotein B (C123), Insulin, Intact, LC/MS/MS (C146), Insulin Resistance Panel with Score (C1388).

If ordering through Quest Diagnostics, panel components are: Cardio IQ® Cholesterol, Total (91717), Cardio IQ® HDL Cholesterol (91719), Cardio IQ® Triglycerides (91718), Cardio IQ® Lipid Panel (91716), Cardio IQ® Hemoglobin A1c (91732), Cardio IQ® Apolipoprotein B (91726), Insulin, Intact, LC/MS/MS (93103), Cardio IQ® Insulin Resistance Panel with Score (36509).

Identifying patients most at risk for severe outcomes from COVID-19 or seasonal flu infection

The risk of more severe outcomes from respiratory viral infections such as COVID-19 increases with preexisting conditions, including cardiovascular disease and Type II diabetes. Review our latest COVID-19 updates.

  • Learn more about how the risk of more severe outcomes from respiratory viral infections such as COVID-19 increases with preexisting conditions, including cardiometabolic disease6,7
  • Quanum® Lab Services Manager allows you to order the tests you need quickly and easily from any device
  • Molecular testing to diagnose active infection and antibody testing to evaluate prior exposure and immune response to the SARS-CoV-2 virus
  • Our Peace of Mind program makes it easier for patients to access routine testing at our Patient Service Centers, with the first hour of each day dedicated to those patients at greater risk

KNOWING more about risk, sooner, can help your patients change course

Learn more about our Metabolic Risk Panel.

 

Download the Metabolic Risk Panel Test Summary

 

Download the Metabolic Risk Panel Case Study: Michael

 

Download the Metabolic Risk Panel Case Study: Lisa

 

Connect with us today, and a Quest sales representative will be in touch

References

  1. Centers for Disease Control and Prevention. About obesity. Accessed June 2, 2020 from https://www.cdc.gov/obesity/about-obesity/index.html
  2. Centers for Disease Control and Prevention. Making healthy living easier: obesity. Accessed June 11, 2020 from https://www.cdc.gov/nccdphp/dnpao/docs/Obesity-Fact-Sheet.pdf
  3. Centers for Disease Control and Prevention. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, national health and nutrition examination survey, 1988–2012. Last updated September 20, 2017. Accessed May 21, 2020 from https://www.cdc.gov/pcd/issues/2017/16_0287.htm
  4. Centers for Disease Control and Prevention. Diabetes and prediabetes. Last updated August 7, 2019. Accessed May 21, 2020 from https://www.cdc.gov/chronicdisease/resources/publications/factsheets/diabetes-prediabetes.htm
  5. Centers for Disease Control and Prevention. Type 2 diabetes. Last updated May 30, 2019. Accessed May 21, 2020 from https://www.cdc.gov/diabetes/basics/type2.html
  6. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648-1655. doi:10.1161/CIRCULATIONAHA.120.046941
  7. American College of Cardiology (ACC). COVID-19 clinical guidance for the cardiovascular care team. Reviewed March 6, 2020. Accessed April 8, 2020 from https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/2020/02/S20028-ACC-Clinical-Bulletin-Coronavirus.pdf